(Reuters) – The New York Stock Exchange opened on Monday after reaching new records during the previous session and while investors are waiting for the speeches of several federal reserve managers (Fed) this week.
The uncertainty surrounding President Donald Trump’s policy in terms of visas for the technological sector also weighs on the feeling of the market.
In the first exchanges, the Dow Jones index loses 156.50 points, or 0.34%, at 46,158.77 points and the Standard & Poor’s 500, wider, fell from 0.21% to 6,650.21 points.
The Nasdaq Composite gives way 0.14%, or 32.45 points, to 22,599.03 points.
The American clues resume their breath at the start of a week which is once again responsible for the monetary policy front, several officials of the American central bank to be expressed in the coming days, notably the new governor Stephen Miran on Monday and President Jerome Powell on Tuesday, after the 25 basis of the rate of the rates decided last week.
This first reduction in borrowing costs of the year and the signs of new decreases during the next Fed meetings have contributed to the recent rebound of Wall Street, just like the renewed enthusiasm for values ​​related to artificial intelligence.
The momentum of the technological sector indeed enabled New York indices to record new records on Friday, but calm seems to have returned Monday after the Trump administration announced that it would ask companies to pay 100,000 dollars per year to obtain an H1-B visa, widely used in this industry.
“The costs and recent visas information indicate an increasingly strict environment that could harm morale,” writes Tien-Tsin Huang, actions analyst at JP Morgan, in a note.
The White House said, however, that this measure, which aroused a general conviction from the leaders of the technological sector, would only apply to new applicants and not to the holders of existing visas.
Being caution, American technological actions are evolving on slight variations this Monday at the start of the session.
On the rest of the business news, the manufacturer of Metsera weight loss drugs climbs more than 59% after the announcement of are redemption by Pfizer (+2%).
* For the values ​​to follow, click on
(Written by Diana Mandiá, edited by Blandine Hénault)
Copyright © 2025 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
